Table 5.
Experimental designs of multiple sclerosis or amyothophic lateral sclerosis – in vivo
| Ref | Model | Sex | Age (w) | N/G | Stem cells | Sacrifice | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Concentration | Im (mg/kg) | Time (day) | Infusion site (AP/ML/DV) | Behavioral test
|
Type | Week | ||||||
| Method | Week | |||||||||||
| 31 | Mice Wr | M | 4 | 48/13 | 105 | CC (15) | 0 | ICV | MRI | 1, 7.1 | 4% PFA | 1, 7.1 |
| 33 | Mice Wr (C57BL/6) | F | 9–10 | 23/2 | 106 | N/A | 7 | ICV (0/1, 0/2, 5) | MRI | 1, 2, 3, 4 | 4% PFA | 2, 3, 4 |
| 32 | Mice Wr | M/F | 4 | 45/3 | 5×105 (5 μL) | N/A | 14 | ICV (0, 5/0, 8/2, 5) | MRI | 7 | 4% PFA | 7 |
| 30 | Mice Wr (C57BL/6) | F | 6–8 | 47/3 | 106 | N/A | 17 | ICV | MRI | −1, 24–48 h, 16–18 d | 4% PFA | 48 h, 18 d |
Abbreviations: Ref, reference; Wr, Woldder; F, female; M, male; w, week; N/G, number of animals/groups; Im, immunosuppression; CC, cyclosporine A; ICV, intracerebroventricular; MRI, magnetic resonance imaging; PFA, paraformaldehyde; AP, anteroposterior; ML, mediolateral; DV, dorsoventral; N/A, not identified; h, hours; d, days.